Table 1.
Constitutive expression and decrease of CXCR4 at the surface of human colorectal carcinoma cells due to anticancer drugs
| Cell line | Basal CXCR4 expression (cpm/105 cells) | Drug treatment | |||
|---|---|---|---|---|---|
| 5-FU | Cis | Vin | MTX | ||
| Maximal decrease (% from control) | |||||
| HT-29 | 470 ± 52 | 75 ± 6.1* | 72 ± 6.3* | 75 ± 12* | 56 ± 7.6* |
| T84 | 220 ± 53 | 42 ± 15 | 48 ± 22 | 27 ± 4.4 | 39 ± 21 |
| HRT-18 | 62 ± 27 | 59 ± 18 | 29 ± 11 | 76 ± 8.4 | 63 ± 27 |
| SW480 | 230 ± 41 | 24 ± 13 | 32 ± 13 | 71 ± 7.6* | 24 ± 6.4 |
| SW620 | 80 ± 29 | 70 ± 7.0 | 77 ± 13* | 72 ± 18 | 73 ± 3.0 |
The relative basal cell-surface protein expression for each cell line was summarized from 8–28 independent experiments. Cells were treated with drugs (5-FU, 5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface expression of CXCR4 was determined by radioimmunobinding assay 48 h later. Maximal decrease of CXCR4 was recorded from 3–8 independent dose–response experiments for each drug and cell line. Data are shown as mean % decreases ± SE. *, significant % decrease due to drug, P < 0.05 using paired t-test